A Placebo Controlled Study of MR901 (Talaporfin Sodium Sodium + a Drug-activating Device) for the Relief of Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia
NCT ID: NCT02326454
Last Updated: 2018-08-08
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
225 participants
INTERVENTIONAL
2014-11-30
2017-03-29
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study of Light-Activated Talaporfin Sodium in Patients With Lower Urinary Tract Symptoms (LUTS) Due to Benign Prostatic Hyperplasia (BPH)
NCT00918034
Clinical Evaluation of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH) NX02-0018
NCT00945490
A Study of Tadalafil in Men With Benign Prostatic Hyperplasia
NCT00970632
Dose Escalation Study With QLT0074 for Benign Prostatic Hyperplasia
NCT00077012
(Phosphodiesterase 5 Inhibitors & α-blockers): Single Versus Combined Therapy in Benign Prostatic Hyperplasia
NCT05236634
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Talaporfin sodium/Light dose 100 J/cm
Single 1 mg/kg dose of talaporfin sodium is administered intravenously with Drug Activator 100 J/cm delivering light for 60 minutes of the 2-hour treatment period
talaporfin sodium
1 mg/kg
Drug Activator 100 J/cm
Light Dose: 100 J/cm
Talaporfin sodium/Light dose 200 J/cm
Single 1 mg/kg dose of talaporfin sodium is administered intravenously with Drug Activator 200 J/cm delivering light for 2 hours
talaporfin sodium
1 mg/kg
Drug Activator 200 J/cm
Light Dose: 200 J/cm
Saline/Light dose 100 J/cm
0.9% Sodium Chloride is administered intravenously with Drug Activator 100 J/cm delivering light for 60 minutes of the 2-hour treatment period
Saline
Drug Activator 100 J/cm
Light Dose: 100 J/cm
Saline/Light dose 200 J/cm
0.9% Sodium Chloride is administered intravenously with Drug Activator 200 J/cm delivering light for 2 hours.
Saline
Drug Activator 200 J/cm
Light Dose: 200 J/cm
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
talaporfin sodium
1 mg/kg
Saline
Drug Activator 100 J/cm
Light Dose: 100 J/cm
Drug Activator 200 J/cm
Light Dose: 200 J/cm
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Documented symptoms of BPH-LUTS for 6 months or more.
3. For patients regularly taking their prescribed BPH medication, dose should have been stable for at least 6 months for 5-alpha reductase inhibitors and 3 months for other BPH medications.
4. For patients who have withdrawn from regularly taking their prescribed BPH medication, there should have been a 6 month washout period for 5-alpha reductase inhibitors and 3 months for other BPH medications.
5. Have a total International Prostate Symptom Score (IPSS; Qs 1-7) of ≥ 15 at both V1 and V2 with a difference between those visits of ≤ 4 points.
6. Prostate volume of 30 - 80 mL (inclusive).
7. Maximum urinary flow rate (Qmax): 5 - 15 mL/sec (assessed on two voids each of ≥ 150mL).
8. Prostate-specific antigen (PSA) ≤10 ng/mL.
9. Post-void residual (PVR) volume ≤200 mL measured by a urinary catheter or bladder ultrasound according to local standard practice.
10. Prostatic urethral length (PUL) of between 30 - 55mm (inclusive) as measured by TRUS.
11. Willing and able to comply with photosensitivity precautions
Exclusion Criteria
2. Subjects weighing \>200 Kg.
3. Subjects with a history or current evidence of any of the following:
1. A bladder disease or condition co-exists, such as idiopathic over-active bladder (OAB) and is evaluated by the Investigator as the predominant etiology for the subject's voiding symptomatology. A score of 4 points or greater on the 3 item OAB Awareness Tool (OABV3) or a high rate of urinary frequency (\>13xday and/or 4x/night) would require investigator specific evaluation in ascribing these symptoms to a bladder condition as opposed to lower urinary tract obstruction. i) If the former is the assessment, then the subject requires exclusion from the study. ii) If the latter is the assessment, then the subject may be deemed eligible for inclusion.
The subject eligibility explanation must be captured in the patient source documents.
2. Active urinary tract infection i.e. must have a screening urinalysis without signs of infection or negative urine culture. Must not have had a previous symptomatic urinary tract infection within 4 weeks of the study.
3. Urethral stricture or any other anatomical feature that would complicate catheterisation.
4. Interstitial cystitis.
5. Predominant prostate middle lobe, as determined by the Investigator.
6. Prostate or bladder cancer or bladder carcinoma-in-situ - in particular, evidence from digital rectal exam (DRE) of prostate abnormalities suggestive of cancer in the last 12 months.
7. Any other absolute indication for urosurgical intervention (such as acute or frequent retention, currently untreated bladder or urethral stones, urethral strictures/bladder neck contracture (BNC)).
8. Damage to the bladder neck which could interfere with study procedures.
4. PSA level in excess of \>10 ng/ml. If the PSA measurement is 2.5-10 ng/ml and/or has shown a clinically significant concerning increase in the last 6 months, local standard of care must be pursued to ensure the possibility of prostate cancer has been followed up and ruled out prior to study entry.
5. Subjects who had had a prostate biopsy within 6 weeks prior to Screening.
6. Any neurological condition affecting the bladder or a history of a neurogenic or chronically decompensated bladder i.e. neurogenic bladder, Parkinson's disease, history of chronic prostatitis within the last 5 years.
7. Prior treatment for urinary incontinence.
8. Requirements for daily incontinence pads or devices.
9. Subjects in whom nocturia is due to etiologies other than their BPH-LUTS, such as neurogenic bladder, diabetic neuropathy, neurocongestive heart failure, hepatic failure, nephritic syndrome, sleep disorder.
10. Previous or concurrent clinically relevant cardiovascular or cerebrovascular disorder within 24 weeks prior to the study i.e. unstable angina pectoris, myocardial infarction, transient ischemic attack, or cerebrovascular accident (stroke) within the past 6 months, or peripheral arterial disease with intermittent claudication or Leriche's syndrome.
11. Presence of serious hepatic diseases, renal diseases, immunological diseases, or pulmonary diseases that are clinically relevant.
12. Unwilling to use contraception for 3 months following administration of study medication or with an interest in future fertility.
13. A prolonged QTcF interval at baseline and/or who are currently taking medication that prolongs QT interval ("prolonged QTcF interval" defined as \> 450 ms).
14. Known sensitivity to porphyrin-type drugs or known history of porphyria.
15. Any contraindications to use of the study treatment.
16. Active alcohol or drug abuse.
17. Subject has clinical laboratory test results outside the reference ranges of the testing laboratory that are deemed to be clinically significant. Subjects with isolated test results that are outside the specified ranges and that are assessed as clinically insignificant will be allowed at the discretion of the Investigator, after discussion with the Sponsor's Medical Monitor/Study Physician, if appropriate. If a subject has 1 isolated test result outside the specific range that is deemed potentially clinically significant, rescreening may be allowed at the discretion of the Investigator, after discussion with the Medical Monitor/Study Physician
18. Subjects with known disorders of coagulation, apart from those receiving anticoagulant / antithrombotic / antiplatelet therapy in whom the dose of such medication must have been stable for at least 1 month prior to randomisation. In those receiving Vitamin K antagonists (warfarin, acenocoumarol, phenindione, etc) the INR value at baseline should be \<3.0.
19. Inability or unwillingness to comply with the required photosensitivity precautions during the three weeks following study treatment.
20. Subjects taking medications with a recognised propensity for causing photosensitivity (such as amiodarone, tetracyclines, sulphonamides) that cannot be discontinued for the initial study period, namely from 14 days prior to administration of study medication until 28 days afterwards.
21. Subjects with medical or investigation results deemed unfit for study treatment, as determined by medical history, clinical laboratory tests, ECG results, and physical examination that, in the Investigator's opinion, preclude entry into the study.
22. Subjects who have received an investigational medicinal product within 30 days or 5 half-lives of the investigational product prior to study entry (defined as the start of the Screening Period).
23. Subjects who are incapable of giving informed consent or complying with the protocol.
40 Years
MALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Mundipharma Research Limited
INDUSTRY
Light Sciences Oncology
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Lisa Koch-Hulle
Role:
LSO
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Anniston, Alabama, United States
Huntsville, Alabama, United States
Anchorage, Alaska, United States
Laguna Hills, California, United States
Los Angeles, California, United States
Murrieta, California, United States
San Diego, California, United States
Tarzana, California, United States
Denver, Colorado, United States
Aventura, Florida, United States
Bradenton, Florida, United States
Coral Gables, Florida, United States
Pompano Beach, Florida, United States
St. Petersburg, Florida, United States
Tampa, Florida, United States
Bloomington, Indiana, United States
Greenwood, Indiana, United States
New Orleans, Louisiana, United States
New Orleans, Louisiana, United States
Greenbelt, Maryland, United States
Towson, Maryland, United States
Chestnut Hill, Massachusetts, United States
Las Vegas, Nevada, United States
Edison, New Jersey, United States
Albuquerque, New Mexico, United States
Garden City, New York, United States
New York, New York, United States
Newburgh, New York, United States
Poughkeepsie, New York, United States
Concord, North Carolina, United States
Cincinnati, Ohio, United States
Middleburg Heights, Ohio, United States
Springfield, Oregon, United States
Bala-Cynwyd, Pennsylvania, United States
Bryn Mawr, Pennsylvania, United States
Myrtle Beach, South Carolina, United States
Knoxville, Tennessee, United States
Dallas, Texas, United States
Houston, Texas, United States
Salt Lake City, Utah, United States
Mountlake Terrace, Washington, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MR901-2501
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.